21 CFR Part 11 was written for a world where humans created every regulated record.
That assumption no longer holds.
For 25+ years, Part 11 has anchored trust in electronic records & signatures. Its core principles haven't changed:
- Records must be complete, accurate & attributable
- Audit trails must show who did what, when & why
- Signatures must be permanently linked to one accountable individual
- Access must be controlled, validated & secure
What has changed is what's creating those records.
AI is now drafting deviation investigations. Summarizing validation evidence. Supporting regulatory submissions. Assisting CAPAs. Preparing risk assessments. Contributing to manufacturing and clinical decision support.
So the compliance question is no longer just:
Who signed the record?
It's now:
Can we demonstrate to a regulator, in an inspection that the knowledge AI generated remains controlled, attributable, traceable & scientifically defensible?
This is exactly where 21 CFR Part 11, FDA's Computer Software Assurance principles, FDA's draft AI credibility framework & the FDA–EMA Good AI Practice principles are converging. Different documents, one message: AI must be governed inside the quality system, not alongside it.
For inspection readiness, that likely means your audit trail package needs to show more than user actions. Depending on intended use and risk, be ready to demonstrate:
- Model version
- Prompt or instruction
- Input context and reference sources
- AI-generated output
- Human review, edits, rationale & final approval
AI can generate content. It cannot assume regulatory accountability.
That responsibility still sits with a named, qualified individual, operating under a validated, risk-based quality system.
Here's what I'm seeing across organizations right now:
Some are deploying AI faster than they're redesigning governance around it. Others are validating the AI tool itself but not the oversight structure surrounding its use.
And the biggest inspection risk isn't AI hallucination.
It's human overconfidence in AI-generated output, unchecked by documented review.
The direction of travel is consistent:
→ Risk-based credibility, not blind trust
→ Human oversight, not human absence
→ Lifecycle governance, not one-time validation
→ Data provenance, not just document retention
The organizations that lead the next decade of pharmaceutical quality will be the ones that can show clearly, consistently, under scrutiny that AI use is controlled, its output is defensible & accountability never left the hands of qualified people.
In the age of AI, the question isn't whether your records are electronic.
It's whether human accountability is still provable.
Read also:
Resource Person: Bharathi Kodali
